BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...partnered with Sotio a.s. and Exelixis Inc. (NASDAQ:EXEL). Neither partnership is affected by the buyout, Damour said.Sotio’s...
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

...diseases company also promoted Sarah Bird was to VP, clinical development from director, clinical development. Sotio a.s....
...a scientist in 2016. Robin Sawka, BioCentury Staff ImCheck Therapeutics S.A.S. IsoPlexis Corp. Abeona Therapeutics Inc. Evaxion Biotech A/S Strongbridge Biopharma plc Sotio a.s. Ixaka...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...Phase I testing for cancer therapy-associated skin rash. MaveriX raises $6.5M in series A, grants Sotio...
...million in an ongoing series A round from PPF Group, the majority owner of oncology-focused Sotio a.s....
...MaveriX is aiming to secure a total of $20 million in the round. Concurrently, Prague-based Sotio...
BioCentury | Apr 5, 2019
Clinical News

Sotio's DCVAC/OvCa improves survival in Phase II for recurrent ovarian cancer

...Data were presented at the Society of Gynecologic Oncology's Meeting on Women's Cancer in Honolulu. Sotio a.s....
...Republic) said it is planning a global Phase III trial of the immunotherapy. Chris Lieu, Staff Writer DCVAC/OvCa Sotio a.s. Ovarian...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...Jan Fagerberg as CMO and Catherine Mathis as chief development officer. Fagerberg was CMO of Sotio a.s....
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...LLC. She succeeds former CFO Klas Themner, who becomes COO. Cancer and autoimmune disease company Sotio a.s....
BioCentury | Jun 1, 2018
Clinical News

Sotio reports PFS data from Phase II of ovarian cancer immunotherapy

...that uses a patient's dendritic cells to induce an immune reaction against presented tumor antigens. Sotio a.s....
...survival (OS) and safety Status: Interim Phase II data Milestone: NA Jennie Walters DCVAC/OvCa American Society of Clinical Oncology Sotio a.s....
BioCentury | Feb 27, 2018
Company News

Management tracks: Sotio, EpimAb

...Cancer and autoimmune disease company Sotio a.s. (Prague, Czech Republic) said CEO Ladislav Bartonícek will transition to...
BioCentury | Dec 8, 2017
Clinical News

Sotio begins Ph II for second-line ovarian cancer candidate

...reaction against presented tumor antigens. Sotio is a subsidiary of European investment firm PPF Group. Sotio a.s....
...OS), objective response rate (ORR), CA-125 and immunological responses Status: Phase II started Milestone: NA Allison Johnson DCVAC/OvCa Sotio a.s. Ovarian...
BioCentury | Apr 14, 2017
Company News

LDC, Max Planck and Sotio deal

...Lead Discovery Center and Max Planck Innovation granted Sotio exclusive rights to an oncology program in...
...target was not disclosed. LDC and its academic partners are to perform lead optimization, and Sotio...
...Planck Innovation GmbH, Munich, Germany SOTIO a.s. , Prague, Czech Republic Business: Cancer Shannon Lehnbeuter Lead Discovery Center GmbH Sotio a.s. Max...
Items per page:
1 - 10 of 15
BioCentury | Dec 10, 2020
Deals

More enthusiasm for ADCs as Boehringer buys NBE, gaining conjugate platform

...partnered with Sotio a.s. and Exelixis Inc. (NASDAQ:EXEL). Neither partnership is affected by the buyout, Damour said.Sotio’s...
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

...diseases company also promoted Sarah Bird was to VP, clinical development from director, clinical development. Sotio a.s....
...a scientist in 2016. Robin Sawka, BioCentury Staff ImCheck Therapeutics S.A.S. IsoPlexis Corp. Abeona Therapeutics Inc. Evaxion Biotech A/S Strongbridge Biopharma plc Sotio a.s. Ixaka...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...Phase I testing for cancer therapy-associated skin rash. MaveriX raises $6.5M in series A, grants Sotio...
...million in an ongoing series A round from PPF Group, the majority owner of oncology-focused Sotio a.s....
...MaveriX is aiming to secure a total of $20 million in the round. Concurrently, Prague-based Sotio...
BioCentury | Apr 5, 2019
Clinical News

Sotio's DCVAC/OvCa improves survival in Phase II for recurrent ovarian cancer

...Data were presented at the Society of Gynecologic Oncology's Meeting on Women's Cancer in Honolulu. Sotio a.s....
...Republic) said it is planning a global Phase III trial of the immunotherapy. Chris Lieu, Staff Writer DCVAC/OvCa Sotio a.s. Ovarian...
BioCentury | Apr 4, 2019
Company News

Management tracks: Gottlieb's next move, plus Vertex, Centogene and more

...Jan Fagerberg as CMO and Catherine Mathis as chief development officer. Fagerberg was CMO of Sotio a.s....
BioCentury | Feb 12, 2019
Company News

Management tracks: Sanofi, Alexion, bluebird

...LLC. She succeeds former CFO Klas Themner, who becomes COO. Cancer and autoimmune disease company Sotio a.s....
BioCentury | Jun 1, 2018
Clinical News

Sotio reports PFS data from Phase II of ovarian cancer immunotherapy

...that uses a patient's dendritic cells to induce an immune reaction against presented tumor antigens. Sotio a.s....
...survival (OS) and safety Status: Interim Phase II data Milestone: NA Jennie Walters DCVAC/OvCa American Society of Clinical Oncology Sotio a.s....
BioCentury | Feb 27, 2018
Company News

Management tracks: Sotio, EpimAb

...Cancer and autoimmune disease company Sotio a.s. (Prague, Czech Republic) said CEO Ladislav Bartonícek will transition to...
BioCentury | Dec 8, 2017
Clinical News

Sotio begins Ph II for second-line ovarian cancer candidate

...reaction against presented tumor antigens. Sotio is a subsidiary of European investment firm PPF Group. Sotio a.s....
...OS), objective response rate (ORR), CA-125 and immunological responses Status: Phase II started Milestone: NA Allison Johnson DCVAC/OvCa Sotio a.s. Ovarian...
BioCentury | Apr 14, 2017
Company News

LDC, Max Planck and Sotio deal

...Lead Discovery Center and Max Planck Innovation granted Sotio exclusive rights to an oncology program in...
...target was not disclosed. LDC and its academic partners are to perform lead optimization, and Sotio...
...Planck Innovation GmbH, Munich, Germany SOTIO a.s. , Prague, Czech Republic Business: Cancer Shannon Lehnbeuter Lead Discovery Center GmbH Sotio a.s. Max...
Items per page:
1 - 10 of 15